Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT03563781 Completed - Sentinel Lymph Node Clinical Trials

SEntine Lymph Node in earLY Ovarian Cancer (SELLY)

SELLY
Start date: November 11, 2017
Phase: N/A
Study type: Interventional

The present study aims at investigating the feasibility, the detection rate and the negative predictive value of sentinel node in predicting the presence or absence of lymph node metastasis in ovarian cancer patients

NCT ID: NCT03562533 Completed - Ovarian Carcinoma Clinical Trials

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Start date: May 17, 2018
Phase:
Study type: Observational

This retrospective multicenter study aimed to evaluate the effectiveness of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with carboplatin and paclitaxel (CP) in patients who had disease progression longer than 6 months after first-line platinum+taxane chemotherapy for ovarian cancer in real world clinical practice.

NCT ID: NCT03561207 Active, not recruiting - Ovarian Cancer Clinical Trials

3D Prediction of Patient-Specific Response

3D-PREDICT
Start date: June 11, 2018
Phase:
Study type: Observational [Patient Registry]

This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.

NCT ID: NCT03558139 Completed - Ovarian Cancer Clinical Trials

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Start date: May 23, 2018
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to investigate the safety and tolerability of magrolimab in combination with avelumab in participants with advanced solid tumors and to confirm the safety and tolerability of this combination and evaluate the anti-tumor activity in participants with checkpoint inhibitor-naive ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma who have previously progressed within 1-6 months of receiving platinum chemotherapy.

NCT ID: NCT03556566 Recruiting - Ovarian Cancer Clinical Trials

Open Label Immunotherapy Trial for Ovarian Cancer

V3-OVA
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This Phase II will evaluate a new type of ovarian cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. We will test new tableted preparation, V3-OVA, obtained from hydrolyzed, inactivated blood and tumors of patients with cancer of ovaries. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

NCT ID: NCT03556228 Recruiting - Breast Cancer Clinical Trials

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Start date: June 8, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

NCT ID: NCT03554434 No longer available - Breast Cancer Clinical Trials

An Expanded Access Program for AM0010 (Pegilodecakin)

Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

NCT ID: NCT03551171 Completed - Ovarian Cancer Clinical Trials

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Start date: December 19, 2017
Phase: Phase 1
Study type: Interventional

Niraparib is a potent and highly selective PARP-1/-2 inhibitor. The primary objective of this trial is to evaluate the pharmacokinetic (PK) properties of ZL-2306 (niraparib) and its metabolite M1 in patients from Mainland China with ovarian cancer, following a single and multiple oral administration of the study drug at the indicated dose (300mg, 200mg or 100mg), once a day.

NCT ID: NCT03549000 Terminated - Ovarian Cancer Clinical Trials

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Start date: July 18, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

NCT ID: NCT03547375 Not yet recruiting - Ovarian Cancer Clinical Trials

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Ovarian Cancer After the Failure of Standard Chemotherapy